The cases cited involved the use of both Tysabri and Avonex, Biogen Idec's existing multiple sclerosis drug. An inquiry into Elan's accounts in 2002 brought the group close to bankruptcy but the firm has been rebuilding itself since, with its share price increasing by almost four-fold last year. "The companies will work with clinical investigators to evaluate Tysabri-treated patients and will consult with leading experts to better understand the possible risk of PML," the two firms said in a statement. "Now there has / there is a question mark over it." Analysts had believed the product would provide a new growth opportunity for Biogen Idec, which had faced increased competition from rivals to Avonex. Elan finished down $18.90 at $8, while Biogen fell $28.63 to $38.65.